Adult

Ertapenem

Warning

General Information

Carbapenem

Restricted formulary antimicrobial: For details see OUH netFormulary

AWaRe antibiotic classification: 'Reserve'. All indications to be discussed with Micro/ID.

For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF.

Standard Dose

 

Intravenous dose

Standard dose

1g OD

Obesity

No dose adjustment required.

  • Note: Micro/ID may recommend a higher dose for an obese patient after considering the organism and its minimum inhibitory concentration

Renal and hepatic impairment

Renal impairment

eGFR (mL/min/1.73m2)

IV dose

More than 30

Dose as in normal renal function

10-30

Use 50-100% of dose

Less than 10

Use 50% of dose or 1g three times a week

HD/HDF/High Flux/PD

1g three times a week

Dialysed; give after dialysis


Hepatic impairment

No dose adjustment required.

MHRA Drug Safety Alerts

MHRA Drug Safety Update (December 2014) Carbapenems: concomitant use with valproic acid not recommended 

  • There is a clinically significant interaction between carbapenems and sodium valproate or valproic acid, which results in reduced valproate plasma concentrations with potential for inadequate seizure control.
  • If the patient is already prescribed sodium valproate or valproic acid and ertapenem is recommended, discuss with Micro/ID and the relevant clinical team. 
  • OUH Weekly Safety Message 365 about Interaction between Sodium Valproate and Carbapenem Antibiotics can be found HERE (February 2026)

References

Editorial Information

Last reviewed: 02 Mar 2026

Next review date: 01 Mar 2029

Author(s): AMST.